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in leukaemias and allied disorders 29-30 October 1996
Bone marrow transplants from unrelated donors for leukaemias are increasing greatly in number and also in proportion to matched sibling
donor transplants. The panel has considered unrelated donor transplant (UD-BMT) on the basis of efficacy, toxicity and indications in
leukaemias. The conclusions and statements are based largely but not exclusively on information provided at the Consensus Conference.
EFFICACY
1. Unrelated bone marrow transplants for some types of
leukaemia can produce prolonged quiescence and, in some
cases, eradication ofdisease.
2. Data based on serologically matched donors at HLA-A,B and
-DR suggest that matched unrelated transplants may have
similar survival to sibling transplants in similar disease states.
This is accepted as a reasonable statement but begs the ques-
tion ofwhat is implied by 'matched' in unrelated transplants.
Much ofthe data concerning the survival and toxicity in unre-
lated transplants have come from studies using serological
typing. The effect ofmolecular typing on outcome may alter
indications.
3. Information on the place ofsibling transplants compared with
chemotherapy and autologous transplants in the management
of some leukaemias has been provided by randomized studies
organized by the EORTC and the MRC. These define the place
of sibling bone marrow transplantation in the management of
acute leukaemias. Conclusions drawn from these studies on
the presence or absence ofbenefit ofsibling transplants may
apply to unrelated transplants.
4. In a few situations, the evidence for efficacy is based on the
level- 1 documentation of zero survival following conventional
therapy but with some survivors following transplant (e.g.
childhood ALL with early bone marrow relapse). However, in
situations in which alternative therapies occasionally succeed,
level-1 evidence from randomized trials is rarely available to
help in decision-making.
5. There is variation in outcome reported from different sources
for particular conditions. In part, this may be because subdivi-
sions ofdifferent types ofleukaemia are not always accurately
defined. Attempts to identify sub-groups and to compare 'like
with like' are essential even though they may make data
collection and comparison more arduous.
6. It is important that rigorous economic evaluations and quality
of life studies are carried out alongside 'like with like'
comparisons.
TOXICITY
1. Increasing age and degree ofmismatch each increase the prob-
ability oftransplant-related mortality and morbidity and need
to be taken into account when assessing the use ofUD-BMT
in any situation. In young (less than 20 years) good-risk
patients, the mortality ofthe procedure is ofthe order of 15%,
which rises in older patients (at 45 years to 30% or more).
2. Transplants with an HLA mismatched (A,B or DR) marrow
have a high toxicity compared with matched marrow and
cannot be equated with sibling transplants.
3. There are, to date, few published studies concerning quality of
life in recipients ofUD-BMT. In order to inform decision-
making, such information must be collected using well-
validated standardized tests.
INDICATIONS
1. Information that allows the classification of various diseases
into good, standard and high risk is essential in allowing
comparative assessment oftreatments including UD-BMT.
2. Evidence suggests that the results ofUD-BMT are better when
performed early in some diseases. The timing ofUD-BMT,
however, depends on the consideration ofother treatment
options.
3. Forpatients with CML in chronic phase or accelerated phase,
UD-BMT should be considered as the best available treatment
at present for patients without a matched sibling donor,
providing that the unrelated donor provides a 'close match'
(level lc evidence).
4. For patients with AML in first remission, UD-BMT has little
place at the present time. In second CR, it may be considered,
although its role in relation to other therapies requires further
evaluation. UD-BMT has a clear place in a subgroup of
patients with initial refractory disease, secondary AML and
high-risk myelodysplastic syndromes (level lc evidence).
5. For a small group ofchildren with very high risk ALL in first
remission, and for children in second remission who have
sustained an early bone marrow relapse, data suggest that
survival may be improved by UD-BMT (level lc evidence).
Similar criteria may apply to adult ALL, but present data are
even more limited.
6. The results ofUD-BMT for desperate disease (such as CML in
blast crisis or acute leukaemia in overt relapse) are discour-
aging (10% or less survival) and are associated with marked
and often unquantitated toxicity. It may be considered that
toxicity inflicted on the unsuccessful recipients negates the
slim chance ofbenefit to those for whom the treatment is
successful in terms of survival.
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INFORMATION FOR DECISION-MAKING
1. UD-BMT should only be carried out when there are facilities
for full characterization ofthe recipient's disease, molecular
HLA typing available and guaranteed reporting to national or
international registries.
2. For conditions which there is no level-I evidence and there is
doubt about the benefits ofUD-BMT vs other therapies, the
procedure is onlyjustified as part of a randomized trial (or
formal pilot for such a trial).
3. With respect to more general planning ofservices, it is impor-
tant to research the issue ofwhether UD-BMT should take
place in a limited number of specialized units.
THE DONORS
1. Peripheral blood stem cell (PBSC) collection has potential
advantages compared with collection ofbone marrow under
general anaesthetic. However, there are uncertainties
concerning short-term and long-term toxicity ofusing granulo-
cyte colony-stimulating factor (G-CSF) with PBSC. This is
inevitable because ofthe small numbers that have been carried
out in healthy donors. It would seem reasonable to offer to
volunteer donors the alternative ofPBSC collection, empha-
sizing the uncertainties - but only when properly informed
consent is possible and agreed standardized protocols are
followed, which include systematic long-term follow-up ofthe
donors.
2. Policies on anonymity differ widely throughout the world.
There are good reasons to maintain strict anonymity between
donor and recipient, despite theoretical problems in donor
recruitment. The potential problems ofbreaking this
anonymity seem to outweigh the benefits ofdisclosure.
Systematic investigation ofthese matters should be carried
out.
3. Further research addressing the complex ethical and psycho-
social issues surrounding related and unrelated donors should
be undertaken.
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